Health Trials

Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG

ConditionsArtificial Intelligence (AI)Cardiac Implantable Electrical DevicesConduction Disorder of the Heart
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-90
SponsorNational Defense Medical Center, Taiwan

About this trial

The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.

Eligibility criteria

Qualifiers

At least one 12-lead ECG within 1 year

Disqualifiers

Diagnosis of sick sinus syndrome

Diagnosis of high-grade or complete atrioventricular block

Diagnosis of ventricular tachycardia or ventricular fibrillation

Post CIED implant

Trial design

Treatments tested in this trial

  • AI-ECG driven ECG monitoring

Treatment groups

11,492 Participants
are divided into 2 treatment groups

Sponsors and collaborators

National Defense Medical Center, Taiwan

Lead sponsor

Source ClinicalTrials.gov